Clinical Trial Update: AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating atorvastatin plus fenofibric acid (TriLipix) for reducing intermediate coronary atherosclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Atherosclerosis

Drugs mentioned

• Fenofibric acid (TriLipix) (fenofibric acid)
• atorvastatin (atorvastatin)

Snippet

Sponsor: Piedmont Healthcare | Conditions: Coronary Atherosclerosis | Phase 3 | Status: WITHDRAWN